Cancer

20 June 2012

Cancer drug price to be halved

The department of health has persuaded pharmaceutical company Roche to halve the price of one of its cancer drugs, Business Day reported.

0

The department of health has persuaded pharmaceutical company Roche to halve the price of one of its cancer drugs, Business Day reported.

The department's deputy director general for regulation Anban Pillay said the drug rituximab, dubbed MabThera by Roche, had previously been too expensive for the state to buy and distribute to patients.

With the price halved, provinces with the capacity to offer cancer treatment will buy the drug, within the constraints of their budgets.

Drug treats multiple diseases

The department’s two-year tender for the drug, shows that government is willing to pay R7950 for a 50ml vial of the injectable rituximab, and R1590 for a 10ml vial.

Rituximab belongs to a class of medicines called biologics, and is used for treating non-Hodgkin’s lymphoma, leukaemia, and severe rheumatoid arthritis.

Roche is a price-setter for MabThera, as the only market with a rival product is India.

Pillay said the department was also in discussion with Roche over a "more affordable" price for its breast cancer drug Herceptin.

(Sapa, June 2012) 

Read more:

Cancer

Chasing cheaper cancer drugs

 

Read Health24’s Comments Policy

Comment on this story
0 comments
Comments have been closed for this article.

Ask the Expert

Cancer expert

CANSA’s purpose is to lead the fight against cancer in South Africa. Its mission is to be the preferred non-profit organisation that enables research, educates the public and provides support to all people affected by cancer. Questions are answered by CANSA’s Head of Health Professor Michael Herbst. For more information, visit cansa.org.za.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules